Health Care Technology
Company Overview of Syapse, Inc.
Syapse, Inc. develops a precision medicine data platform that enables laboratories, registries, and healthcare providers to use molecular profiling to diagnose and treat patients. It offers Syapse precision medicine data platform that enables academic and community healthcare providers to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. The company’s Syapse enables providers to implement omics-based clinical decision support; labs to streamline everyday lab technician activities; medical directors to assemble patient data and curated knowledge into reports; bioinformaticists to g...
101 University Avenue
Palo Alto, CA 94301
Founded in 2008
Key Executives for Syapse, Inc.
Co-Founder, Chairman and Chief Executive Officer
Co-Founder and Chief Technology Officer
Vice President of Customer Solutions
Director of Customer Solutions
Compensation as of Fiscal Year 2015.
Syapse, Inc. Key Developments
Caris Life Sciences and Syapse Collaborate to Aggregate Oncology Data
Nov 18 15
Caris Life Sciences and Syapse announced a collaboration to collect and combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network (COE Network). The COE Network consists of cancer centers that have demonstrated a commitment to precision medicine and are working collaboratively to establish improved standards of care for molecular tumor profiling in oncology. Integration of Caris Molecular Intelligence, Caris' panomic, comprehensive tumor profiling service, with the Syapse Precision Medicine Platform, will provide a powerful real-time, point-of-care, clinical decision support system to enable more informed treatment decisions for each individual patient. Participating COE Network sites can use the integrated decision support system, and may use Syapse to further support their complete precision medicine workflows. The collaboration enables patient outcomes data to be combined with the most comprehensive and clinically actionable molecular profile available. Caris Molecular Intelligence uses multiple technology platforms, including a proprietary 592-gene Next-Generation Sequencing (NGS) panel with full gene coverage to assess point mutations, indels, and copy number variations, alongside RNAseq, for select gene fusions, in addition to Immunohistochemistry (IHC), in situ Hybridization (ISH), and other platforms. This comprehensive interrogation of DNA, RNA, and protein expression enables Caris to include critical companion diagnostics for biomarkers such as ALK, ROS, HER2 and PDL1, and to provide associations for three key therapeutic classes: targeted therapies, immunotherapies and chemotherapeutics. Under the agreement, Syapse software will be used to enable the COE Network to develop a better understanding of cancer and the most effective means of treatment and to provide patients with better access to new therapies and clinical trials. Select COE Network members will use Syapse to capture key oncology-specific clinical data from electronic medical records, integrate clinical data with Caris Molecular Intelligence tumor profiling results, and aggregate de-identified data into Caris' centralized instance of the Syapse Precision Medicine Platform for sharing across the COE Network. In addition, Syapse will enable COE Network members to participate in virtual tumor boards, where they can review cases, capture guidance, and disseminate knowledge throughout the Network.
Syapse Announces Executive Appointments; Opens East Coast Office
Oct 2 14
Syapse, announced the expansion of its Customer Solutions team to support its rapidly growing client base of healthcare provider organizations. Andreas Heid has been appointed VP of Customer Solutions, and Michael Italia joins as Director of Customer Solutions. Andreas Heid brings 13 years of experience at Siemens in creating, deploying, and managing enterprise software solutions used at Siemens and its clients. For the past two years, Andreas was Senior Director of Cloud & Applications at Siemens Healthcare Diagnostics, where he led the development of a cloud-based analytics platform for companion diagnostics. In his role as VP of Customer Solutions, Andreas will be responsible for the implementation of Syapse software at healthcare provider systems, and will join the Syapse executive leadership team. Michael Italia joins Syapse from Children's Hospital of Philadelphia, where he spent five years building and deploying clinical decision support applications to help physicians use complex genomic and clinical data within their electronic medical record workflow.
In his role as Director of Customer Solutions, Michael will open a Syapse office in Philadelphia to support clients on the East Coast. Samantha Chui, who previously led both Customer Solutions and Product Management, will now have full-time responsibility for Product Management at Syapse.
Intermountain Healthcare and Syapse Collaborate to Improve Access to Clinical Genomics for Community Oncologists
May 29 14
Intermountain Healthcare and Syapse announced a collaboration to bring genomics-driven precision cancer care to oncologists within the Intermountain system and also worldwide. This new clinical service, Intermountain Cancer Genomics, will provide cost-effective, genomics-driven, personalized treatment planning through easy-to-use software. Intermountain Cancer Genomics is a comprehensive clinical service providing tumor genome profiling, analysis of genomic data from a molecular tumor board, targeted therapy options, drug procurement, and outcomes analysis. The service leverages Intermountain's in-house infrastructure, which includes a clinical sequencing laboratory and an affiliated health insurance plan. The integrated service utilizes a molecular tumor board to develop treatment options from genomic testing results, in order to effectively procure targeted therapeutics. Quality-of-life issues also factor prominently in treatment plan development. Syapse software will power Intermountain Cancer Genomics. Using Syapse's web-based interface, oncologists will be able to order molecular tests, view genomic results and molecular tumor board interpretation, make a treatment selection, and order drugs targeted to a patient's specific genomic makeup. Syapse software integrates data from multiple source systems to provide oncologists with a unified view of their patients' clinical and genomics data, while also tracking patient outcomes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|